Related Experiment Video

Updated: Jun 5, 2026

Antibody Transfection into Neurons as a Tool to Study Disease Pathogenesis
06:56

Antibody Transfection into Neurons as a Tool to Study Disease Pathogenesis

Published on: September 26, 2012

Reduced thymic expression of ErbB receptors without auto-antibodies against synaptic ErbB in myasthenia gravis

Kathleen Vrolix1, Erik H Niks, Rozen Le Panse

  • 1Department of Neuroscience, School of Mental Health and Neuroscience, Faculty of Health, Medicine and Life Sciences, Maastricht University, Universiteitssingel 50, P.O. Box 616, 6200 MD Maastricht, The Netherlands.

Journal of Neuroimmunology
|December 21, 2010
PubMed

Insights

Researchers investigated ErbB proteins in idiopathic myasthenia gravis (MG) patients. Reduced ErbB4 mRNA was found in thymuses, but no anti-ErbB antibodies were detected, ruling out ErbB receptors as auto-antigens in this MG subset.

Area of Science:

  • Neurology
  • Immunology
  • Molecular Biology

Background:

  • Myasthenia gravis (MG) involves impaired neuromuscular transmission, often due to auto-antibodies targeting acetylcholine receptors (AChR) or MuSK.
  • A subset of MG patients, termed idiopathic MG (iMG), lack identified auto-antigens.
  • ErbB proteins are implicated in regulating AChR density at the neuromuscular junction (NMJ).

Purpose of the Study:

  • To investigate the potential role of ErbB proteins as auto-antigens in iMG.
  • To explore the association between ErbB4 expression and iMG.
  • To determine if anti-ErbB antibodies are present in iMG patient sera.

Main Methods:

  • Analysis of ErbB4 mRNA expression in thymus tissue from iMG, AChR-MG, and non-MG control groups.
  • Screening of iMG patient sera for the presence of anti-ErbB antibodies.

Main Results:

  • Significantly reduced ErbB4 mRNA expression was observed in the thymus tissue of iMG patients compared to AChR-MG and non-MG controls.
  • No anti-ErbB antibodies were detected in the sera of iMG patients.

Conclusions:

  • The findings do not support a role for ErbB receptors as auto-antigens in iMG.
  • Reduced ErbB4 mRNA expression in the thymus may indicate a different underlying mechanism in iMG pathogenesis.
  • Further research is needed to identify the auto-antigens in idiopathic myasthenia gravis.

More Related Videos

Antigenic Liposomes for Generation of Disease-specific Antibodies10:31

Antigenic Liposomes for Generation of Disease-specific Antibodies

Published on: October 25, 2018

Related Concept Videos

Myasthenia Gravis ll: Pathophysiology01:22

Myasthenia Gravis ll: Pathophysiology

The disease process of myasthenia gravis begins at the neuromuscular junction, where antibodies attack key proteins needed for muscle activation. This immune reaction weakens signal transmission, leading to the characteristic muscle fatigue and weakness that define the condition.Immune-Mediated DamageIn most individuals, antibodies target acetylcholine receptors (AChRs) on the postsynaptic membrane of muscle cells. By blocking acetylcholine binding, these antibodies prevent the nerve signal...
Myasthenia Gravis: Overview and Treatment01:20

Myasthenia Gravis: Overview and Treatment

Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...
Myasthenia Gravis: Diagnostic Tests01:15

Myasthenia Gravis: Diagnostic Tests

Myasthenia gravis is an autoimmune condition affecting neuromuscular transmission, causing generalized weakness in skeletal muscles. Initial diagnoses rely on patients' signs, symptoms, and medical history. The challenge lies in distinguishing myasthenia from other muscular dystrophies. An important diagnostic feature is the significant improvement of symptoms after administering anticholinesterase inhibitors.
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
Chemical Synapses01:26

Chemical Synapses

Chemical synapses are specialized sites between two neurons or between a neuron and a non-neuronal cell like a muscle, glandular or sensory cell.
Because chemical synapses depend on the release of neurotransmitter molecules from synaptic vesicles to pass on their signal, there is an approximately one millisecond delay between when the axon potential reaches the presynaptic terminal and when the neurotransmitter leads to opening of postsynaptic ion channels. Additionally, this signaling is...
Chemical Synapses01:26

Chemical Synapses

Chemical synapses are specialized sites between two neurons or between a neuron and a non-neuronal cell like a muscle, glandular or sensory cell.
Because chemical synapses depend on the release of neurotransmitter molecules from synaptic vesicles to pass on their signal, there is an approximately one millisecond delay between when the axon potential reaches the presynaptic terminal and when the neurotransmitter leads to opening of postsynaptic ion channels. Additionally, this signaling is...
Receptor Downregulation in MVBs01:15

Receptor Downregulation in MVBs

Multivesicular bodies (MVBs) are mature endosomes that sort ubiquitinated proteins and then fuse with lysosomes to degrade the sorted proteins. Epidermal growth factor (EGF) and its receptor (EGFR) form a complex that can be internalized through endocytosis, sorted into an MVB, and later degraded.
The EGFR can initiate signaling pathways that  lead to cell proliferation, migration, and differentiation. Overexpression of EGFR  stimulates cells to proliferate. Excessive  EGFR activation may...